Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06472661 · ClinicalTrials.gov registry record · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
A Early Phase 1 study of Advanced Melanoma, sponsored by University of Virginia.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 11
- Enrollment target
- 1
- Study location
NCT06472661: Recruiting Early Phase 1 study of Advanced Melanoma, sponsored by University of Virginia.
NCT06472661 is a Early Phase 1 study of Advanced Melanoma that is actively recruiting participants, run by University of Virginia. The registered enrollment target is 11 participants, below the 171-participant average among 21 other Advanced Melanoma trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06472661, a Early Phase 1 study of Advanced Melanoma, is actively recruiting participants, sponsored by University of Virginia.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 11 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is for adult patients with advanced melanoma who are receiving immunotherapy and who are planning on having surgery for their cancer. All participants in this study will receive an experimental treatment made up of focused ultrasound ablation (FUSA), a non-invasive experimental treatment that uses ultrasound waves to heat and destroy tumor tissue, and an injection in the tumor with an experimental drug that activates the immune system called polyICLC (polyinosinic-polycytidylic acid that is stabilized with carboxymethylcellulose and polylysine). Neither the drug nor the device that are used in this study have been approved by the U.S. Food and Drug Administration (FDA).
Primary Outcome
Incidence and severity of adverse events (Common Terminology Criteria for Adverse Events \[CTCAE\] v5).
Conditions Studied
Interventions
- DEVICE Echopulse or Echopulse HD
- DRUG PolyICLC
Study Locations (1)
Virginia
- University of Virginia - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2024-09-27 |
| Est. Completion | 2026-08 |
| Phase | Early Phase 1 |
What NCT06472661 shows while recruiting
NCT06472661 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 171-participant average among 21 other Advanced Melanoma trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Advanced Melanoma appearing as the primary indexed condition, and to 2 interventions - of which Echopulse or Echopulse HD is the first listed.
NCT06472661 reports a single indexed study location in Virginia.
Frequently Asked Questions
What is clinical trial NCT06472661 about?
NCT06472661 is a clinical study titled "FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma". This study is for adult patients with advanced melanoma who are receiving immunotherapy and who are planning on having surgery for their cancer. All participants in this study will receive an experimental treatment made up of focused ultrasound ablation (FUSA), a non-invasive experimental treatment ...
What is the current status of trial NCT06472661?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 11 participants. The study started on 2024-09-27. Estimated completion is 2026-08.
What conditions does trial NCT06472661 study?
This clinical trial studies the following conditions: Advanced Melanoma.
What interventions are being tested in trial NCT06472661?
The interventions under investigation include: Echopulse or Echopulse HD (DEVICE), PolyICLC (DRUG).
Who is sponsoring clinical trial NCT06472661?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06472661 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06472661's enrollment target sits among peer trials
11 21st of 21 higher than 1 of 21 other Advanced Melanoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
RECRUITING · Phase 1
-
The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor Cancers Being Treated With Standard of Care Checkpoint Inhibitors
RECRUITING · Phase 1
-
AB821 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
RECRUITING · Phase 3
-
Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
RECRUITING · Phase 2
-
High-Intensity Exercise and High-Fiber Diet for Immunotherapy Outcomes in Melanoma Patients: The DUO Trial
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06673329 · 11 participants · Phase 1
Brodalumab in the Treatment of Immune-Related Adverse Events
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI